Company news
Beijing Foyou Pharma Co., Ltd. news in 2025
Beijing Foyou Pharma Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Change of Investor Contact Number
December 26, 2025
Announcement on Completion of Industrial and Commercial Filing
December 18, 2025
Announcement on Approval Notice for Clinical Trials of Ketoprofen Gel Patch
November 27, 2025
Announcement on the Election of Employee Directors and the Adjustment of Audit Committee Members
November 14, 2025
Announcement on Obtainment of the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I)
November 11, 2025
Announcement on Proposed Selection in the 11th National Centralized Drug Procurement
October 29, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 28, 2025
Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets
October 21, 2025
Announcement on Obtaining Drug Registration Certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II)
September 29, 2025
Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (15 mg/850 mg)
September 16, 2025
Announcement on Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets
September 8, 2025
Announcement on Obtaining Drug Registration Certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules
September 4, 2025
Announcement on Obtaining Drug Registration Certificate for Levothyroxine Sodium Tablets
August 26, 2025
Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Supervisors
August 18, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 14, 2025
Announcement on Wholly-owned Subsidiary Changing Business License
August 13, 2025
Announcement on Abnormal Fluctuations in Stock Trading
August 4, 2025
Announcement on Obtaining Drug Registration Certificate for Lansoprazole Enteric Capsules
July 31, 2025
Announcement on Approval Notice of the Supplementary Application for Drugs Obtained by the Subsidiary
July 30, 2025
Announcement on Obtaining Drug Registration Certificate for Bifonazole Solution
July 29, 2025
Announcement on Obtaining Drug Registration Certificate for Amorolfine Hydrochloride Liniment
July 4, 2025
Announcement on Obtaining Drug Registration Certificate for Benidipine Hydrochloride Tablets
July 1, 2025
Announcement on Listing and Circulation of Restricted Shares in Initial Public Offering
June 24, 2025
Announcement on Obtaining Drug Registration Certificate for Acipimox Capsules
June 10, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Ketoprofen Patch
June 5, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Lidocaine Prilocaine Cutaneous Spray Solution
May 29, 2025
Announcement on the Completion of Term Change and Election of Board of Directors and Board of Supervisors and Appointment of Senior Management Members, Head of Audit Department and Securities Affairs Representative
May 28, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
May 27, 2025
Announcement on Resolutions of the 17th Meeting of the 2nd Board of Directors
April 29, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
April 28, 2025
Announcement on Obtaining Drug Registration Certificate for Rosuvastatin Calcium and Ezetimibe Tablets (I)
April 25, 2025
Announcement on Convening the Q1 2025 Performance Briefing
April 24, 2025